SEC Form 4 
FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 	  
OMB APPROVAL
OMB Number:	3235-0287	
Estimated average burden	
hours per response:	0.5	

	
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			
1. Name and Address of Reporting Person*
LILLY ELI & CO	

(Last)	(First)	(Middle)	
LILLY CORPORATE CENTER	

(Street) 
INDIANAPOLIS	IN	46285	

(City)	(State)	(Zip)	
	2. Issuer Name and Ticker or Trading Symbol 
Aeglea BioTherapeutics, Inc. [ AGLE ] 	5. Relationship of Reporting Person(s) to Issuer 
(Check all applicable) 
	Director	X	10% Owner	
	Officer (give title below)		Other (specify below)	

	3. Date of Earliest Transaction (Month/Day/Year)
04/12/2016 		
	4. If Amendment, Date of Original Filed (Month/Day/Year)
04/14/2016 	6. Individual or Joint/Group Filing (Check Applicable Line) 
	Form filed by One Reporting Person	
X	Form filed by More than One Reporting Person	
	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned	
1. Title of Security (Instr. 3) 	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8) 	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 	7. Nature of Indirect Beneficial Ownership (Instr. 4) 	
			Code	V	Amount	(A) or (D)	Price				
Common Stock	04/12/2016		C		2,010,924	A	$0(1) 	2,068,543	I	by fund(2)(3) 	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities) 	
1. Title of Derivative Security (Instr. 3) 	2. Conversion or Exercise Price of Derivative Security 	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) 	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 	8. Price of Derivative Security (Instr. 5) 	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 	11. Nature of Indirect Beneficial Ownership (Instr. 4) 	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
1. Name and Address of Reporting Person*
LILLY ELI & CO	

(Last)	(First)	(Middle)	
LILLY CORPORATE CENTER	

(Street) 
INDIANAPOLIS	IN	46285	

(City)	(State)	(Zip)	
	
1. Name and Address of Reporting Person*
Lilly Ventures Fund I LLC	

(Last)	(First)	(Middle)	
115 W. WASHINGTON STREET	
SUITE 1680 SOUTH	

(Street) 
INDIANAPOLIS	IN	46204	

(City)	(State)	(Zip)	
	
1. Name and Address of Reporting Person*
Shanafelt Armen	

(Last)	(First)	(Middle)	
C/O LILLY VENTURES	
115 W. WASHINGTON STREET, STE 1680 SOUTH	

(Street) 
INDIANAPOLIS	IN	46204	

(City)	(State)	(Zip)	
	
Explanation of Responses:	
1. In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.	
2. These shares are owned directly by Lilly Ventures Fund I LLC (the "Fund"). LV Management Group LLC (the "Management Company") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein.	
3. This line item is being re-reported in order to gain access to the filing system. This Form is being amended to include Reporting Owners, Lilly Ventures Fund I LLC, and Dr. Shanafelt Armen as beneficial owners of the shares reported in the Form 4, previously filed by Eli Lilly and Company on April 14, 2016.	
Remarks:	
	
	Tiffany R. Benjamin, Authorized Person, authorization on file	04/14/2016	
	** Signature of Reporting Person	Date	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).	
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.